Drug Profile
Research programme: complement pathway inhibitors - Attune Pharmaceuticals
Latest Information Update: 04 Jan 2023
Price :
$50
*
At a glance
- Originator Attune Pharmaceuticals
- Class Small molecules
- Mechanism of Action Complement system protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Immunological disorders
Most Recent Events
- 04 Jan 2023 Preclinical trials in Immunological disorders (Prevention) in USA (PO), prior to January 2023 (Attune pharmaceutical pipeline, January 2023)
- 28 Apr 2021 No recent reports of development identified for research development in Immunological-disorders(Prevention) in USA (PO)
- 01 Mar 2017 Early research in Immunological disorders (Prevention) in USA (PO), before March 2017 (Attune Pharmaceuticals website)